Biological
Oncolytic Virus clinical trials
- studies test it
- 13
- open now
- 4
- in phase 3
- 1
- first study started
- 2014
Keep track of what changes. Save the Oncolytic Virus studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 9
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · The First Affiliated Hospital of Bengbu Medical University (2) · Beijing Neurosurgical Institute (1) · Mianyang Central Hospital (1) · Sichuan University (1) · CG Oncology, Inc. (1) · North China Petroleum Bureau General Hospital (1) · First Affiliated Hospital Bengbu Medical College (1)
Studies
Open first, then newest update. How each study uses Oncolytic Virus is read from its arms, and is right about nine times in ten.
Testing it · 13
- Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid TumorsEnrolling by invitationEarly Phase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07656090Written as Oncolytic Virus injection(IDOV-Immune)
- Clinical Study of Oncolytic Virus in GlioblastomaRecruitingPhase 1/2Mianyang Central HospitalNCT07145047Written as oncolytic virus
- Oncolytic Virus in Esophageal Squamous Cell CarcinomaRecruitingPhase 1/2Sichuan UniversityNCT07061704Written as Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses.
- Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid TumorsRecruitingEarly Phase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06346041Written as Oncolytic Virus injection(IDOV-SAFETM)
- Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant GliomaCompletedPhase 1/2Beijing Neurosurgical InstituteNCT06562621Written as ON-01
- Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid TumorsStatus unknownPhase 1North China Petroleum Bureau General HospitalNCT04787003Written as oncolytic virus (OVV-01) injection
- A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid TumorsStatus unknownPhase 1The First Affiliated Hospital of Bengbu Medical UniversityNCT05205408Written as Oncolytic Virus Injection(RT-01)
- A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung CancerStatus unknownPhase 1First Affiliated Hospital Bengbu Medical CollegeNCT05205421Written as Oncolytic Virus Injection(RT-01)
- Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell LymphomaStatus unknownPhase 1The First Affiliated Hospital of Bengbu Medical UniversityNCT05387226Written as Oncolytic Virus Injection(RT-01)
- A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid TumorsStatus unknownPhase 1The Affiliated Hospital of Xuzhou Medical UniversityNCT05228119Written as Oncolytic Virus Injection(RT-01)
- Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical StudyStatus unknownEarly Phase 1Shanghai Fengxian District Central HospitalNCT05180851Written as Recombinant L-IFN adenovirus injection
- A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid TumorsStatus unknownPhase 1Wuxi People's HospitalNCT05136937Written as Oncolytic Virus Injection(RT-01)
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerTerminatedPhase 2/3CG Oncology, Inc.NCT01438112Written as CG0070 Adenovirus Vector